Therapeutical Class：Glycopeptide, interferes the cell-wall biosynthesis of bacteria by inhibiting the polymerization of peptidoglycan

Indication：Staphylococcus, Enterococcus, C. difficle.

Administraton：IM or IV.

Adults: 3-12 mg/kg/day, with loading dose 6 mg/kg q12h for 3 doses.

Children: 10 mg/kg q12h for 3 doses, then 6-10 mg/kg qd.

Neonates: loading dose of 16 mg/kg followed by 8 mg/kg qd.

Renal impairment: Ccr 40-60 ml/min, administer 50% of usual dose;

Ccr <40 ml/min and HD, administer 30% of usual dose;

CAPD, single loading dose 400 mg, and 20 mg/L/bag in the first week, 20 mg/L/bag in the second week and 20 mg/L in the overnight dwell bag only during the third wk.

Adverse Effect：Local irritation at the injection site, rash, nausea, vomiting, diarrhea, flushing, pruritus, fever, bronchial spasm, eosinophilia, leukopenia, elevated transaminase and alk. Phosphatase, dizziness.

Pregnancy Risk：

Supply：Targocid XE “Targocid” Inj 200mg（得時高凍晶注射劑 Aventis）＜02099＞